Two-year data show new Novartis drug Jakavi® significantly reduced myelofibrosis disease burden and suggest overall survival advantage
19:16 EST 10 Dec 2012 | Thomson Reuters
This article has expired, however you can still
download the PDF.
Preview:
Novartis International AG /
Two-year data show new Novartis drug Jakavi® significantly reduced myelofibrosis
disease burden and suggest overall survival advantage
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for t...
Other Sources for this Article
More From BioPortfolio on "Two-year data show new Novartis drug Jakavi® significantly reduced myelofibrosis disease burden and suggest overall survival advantage"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
